Summit Toxicology, L.L.P., P.O. Box 427, Allenspark, CO 80510, USA.
Int J Hyg Environ Health. 2012 Feb;215(2):145-8. doi: 10.1016/j.ijheh.2011.09.011. Epub 2011 Dec 20.
Human biomonitoring (HBM) has proven an extremely valuable tool for determining which chemicals are getting into people, detecting trends in population exposures over time, and identifying populations with exposures above background. The potential significance of the HBM data in the context of existing toxicology data and risk assessments can be assessed if chemical-specific quantitative screening criteria are available. Such screening criteria would ideally be based on robust datasets relating potential adverse effects to biomarker concentrations in human populations. However, such assessments are data intensive and exist for only a few chemicals. As an interim approach, the concept of Biomonitoring Equivalents (BEs) has been developed. A Biomonitoring Equivalent (BE) is defined as the concentration or range of concentrations of a chemical or its metabolites in a biological medium (blood, urine, or other medium) that is consistent with an existing health-based exposure guidance value such as a Reference Dose (RfD) or Tolerable or Acceptable Daily Intake (TDI or ADI). This paper provides an overview of the derivation of BEs and how BEs can be used to interpret human biomonitoring data in a public health risk context.
人体生物监测 (HBM) 已被证明是一种非常有价值的工具，可用于确定哪些化学物质进入人体，检测人群暴露随时间的趋势，并确定暴露于背景之上的人群。如果有针对特定化学物质的定量筛选标准，就可以评估 HBM 数据在现有毒理学数据和风险评估背景下的潜在意义。此类筛选标准最理想的情况是基于与人群中生物标志物浓度相关的潜在不良影响的稳健数据集。然而，此类评估需要大量数据，并且仅适用于少数几种化学物质。作为一种临时方法，已经提出了生物监测等效物 (BE) 的概念。生物监测等效物 (BE) 定义为与现有基于健康的暴露指导值（如参考剂量 (RfD) 或可耐受或可接受日摄入量 (TDI 或 ADI)）一致的化学物质或其代谢物在生物介质（血液、尿液或其他介质）中的浓度或浓度范围。本文概述了 BE 的推导方法以及如何在公共健康风险背景下使用 BE 来解释人体生物监测数据。
